mRNA/saRNA Manufacturing
Considerations to Accelerate the Path to Clinic
| region | na1 |
| portalId | 1769030 |
| formId | 82c71d50-0226-4511-889e-0f98425370e7 |
| target | services-hubspot-form |
| redirectUrl | https://www.aldevron.com/thank-you-for-downloading-mrna/sarna-manufacturing-considerations-to-accelerate-the-path-to-clinic-part-2 |
mRNA/saRNA Questions Answered: Part Two
Aldevron Chief Scientific Officer, Venkata Indurthi, answered many of the questions he received during his webinar titled, “mRNA/saRNA Manufacturing – Considerations to Accelerate the Path to Clinic”. This 16-page transcript is the second of two and answers 30+ questions asked by the live audience, examples include:
- Is there any difference between optimizing saRNA and mRNA optimization?
- What assays can be used to assess the extent or amount of dsRNA? Do you directly measure immune response or protein kinase activity related to dsRNA?
- What are the advantages and disadvantages of enzymatic capping compared with co-transcriptional capping?
- What are major analytical challenges faced while working with integrity tests?